AstraZeneca’s New Study: Exploring Ceralasertib’s Impact on Drug Interactions

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca, in collaboration with Parexel International, is conducting a Phase I study titled A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours. The study aims to assess how ceralasertib affects the pharmacokinetics of three other drugs in patients with advanced solid tumors, providing insights into potential treatment combinations.

The intervention involves administering ceralasertib, an experimental drug, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily for a week, while the other drugs are administered in single doses at specific intervals to observe interactions.

This open-label study follows a single-group, fixed-sequence design with no masking. Its primary purpose is to explore treatment effects, focusing on how ceralasertib influences the pharmacokinetics of the other drugs.

The study began on May 21, 2025, with the latest update on August 14, 2025. These dates mark the study’s progress and ensure transparency in its development.

For investors, this study could impact AstraZeneca’s stock performance by potentially enhancing its oncology portfolio. The collaboration with Parexel may also strengthen investor confidence. However, the competitive landscape in oncology remains intense, with numerous players seeking breakthroughs.

The study is currently recruiting, with further details available on the ClinicalTrials portal.